Prevention of influenza disease caused by the 2 influenza A virus subtypes & the 2 influenza B virus types contained in the vaccine for active immunisation of adults, including pregnant women, & childn ≥6 mth of age; & passive protection of infants from birth to <6 mth of age following vaccination of pregnant women.
IM/SC Adult 1 dose of 0.5 mL. Childn 6 mth to 17 yr 1 dose of 0.5 mL, <9 yr (not previously vaccinated) Give a 2nd dose of 0.5 mL after an interval of at least 4 wk. Passive protection of infant Give 1 dose of 0.5 mL to pregnant women.
Hypersensitivity to flu vaccine or to any component that may be present as traces eg, eggs (ovalbumin, chicken proteins), neomycin, formaldehyde & octoxinol-9. Postpone vaccination in case of moderate or severe febrile disease or acute disease.
Anaphylactic reaction following vaccination. Administer w/ caution to patients w/ thrombocytopaenia or bleeding disorder. Syncope (fainting) can occur as psychogenic response to needle inj. Do not administer intravascularly. Ab response in patients w/ endogenous or iatrogenic immunosuppression may be insufficient. Interference w/ serological testing. Not all infants <6 mth of age born to women vaccinated during pregnancy will be protected (passive protection). Safety & efficacy of active immunisation have not been established in infants <6 mth of age.
Immunological response may be reduced w/ immunosuppressants. Can be given at the same time as other vaccines in separate inj sites & separate syringes.
Sign Out
